PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II/III trial

BACKGROUND: PTPRZ1-MET fusion was reported to associate with glioma progression from low-grade to high-grade glioma, which was a target by a MET inhibitor vebreltinib. However, little is known about the further efficacy of vebreltinib among more glioma patients. This trial aims to evaluate the safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Zhaoshi, Li, Shouwei, Wang, Liang, Zhang, Bisi, Zhang, Peilong, Shi, Hepeng, Qiu, Xiaoguang, Jiang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347714/
https://www.ncbi.nlm.nih.gov/pubmed/37443050
http://dx.doi.org/10.1186/s41016-023-00329-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347714/
https://www.ncbi.nlm.nih.gov/pubmed/37443050
http://dx.doi.org/10.1186/s41016-023-00329-0

Ejemplares similares